Use of micronized palmitoylethanolamide and trans-polydatin in chronic pelvic pain associated with endometriosis. An open-label study

Abstract

riassunto: Palmitoiletanolamide micronizzata + trans-Polidatina nel dolore pelvico cronico associato ad endometriosi. Studio pilota in aperto.

Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence

“…The included articles report results from nine RCTs [15][16][17][23][24][25][26][27][28] and nine [18][19][20][21][22][29][30][31][32] observational studies. Five [18][19][20][21][22] of the observational studies used a comparative design, and four [29][30][31][32] had no comparator group, instead comparing post-treatment pain scores with baseline values.…”

“…Major methodological differences (Table 1) in eligibility requirements, treatment allocation, and outcome assessments should be considered in conjunction with the findings. Of the 18 studies, nine [16,[22][23][24][25][26][27][28]32] required a surgical diagnosis of endometriosis, five [18,20,21,29,31] used radiologic criteria, and four [15,17,19,30] allowed either method. Whereas surgery can detect endometriosis at any stage, radiologic methods only detect moderate-to-severe disease (33,34).…”

The role of the endocannabinoid system in aetiopathogenesis of endometriosis: A potential therapeutic target

“…PEA with transdatin resulted in significant improvement in both mental and physical component of the SF-12 quality of life questionnaire, while two hormonal therapy groups resulted in significant improvement only in the physical component [64]. A prospective study with 56 women assessed the effects of PEA with transdatin on pain, quality of life and sexual function using the visual analogic scale (VAS), quality of life questionnaire (SF-36), Female Sexual Function Index (FSFI), and the Female Sexual Distress Scale (FSDS) and reported improvement in pain symptoms, all categories of the SF-36 quality of life questionnaire and FSFI and FSDS score by the 6 th and 9 th month [65].…”

“…PEA in combination with polydatin, a phytoalexin polyphenolic compound that downregulates inflammation, significantly decreased endometriosisrelated dysmenorrhoea, dyspareunia and pelvic pain compared to placebo after 3 months [62]. Furthermore PEA with polydatin was found to be as effective as hormonal therapies including leuprorelin acetate (synthetic analogue of GnRH) and ethinylestradiol + drospirenone in reducing endometriosis related pain symptom without the anti-ovulatory effects [64]. A recent metaanalysis evaluating clinical effectiveness of PEA with polydatin in reducing endometriotic chronic pelvic pain concluded that it resulted in clinically relevant improvement of chronic pelvic pain and dysmenorrhoea while improving deep dyspareunia to a limited degree [66].…”

“…There have been a number of studies and a meta-analysis investigating the effects of PEA on endometriosis pain symptoms and quality of life (Table 3) [61][62][63][64][65][66]. PEA in combination with polydatin, a phytoalexin polyphenolic compound that downregulates inflammation, significantly decreased endometriosisrelated dysmenorrhoea, dyspareunia and pelvic pain compared to placebo after 3 months [62].…”